Cytokinetics Announces CK-2017357 Receives Fast Track Designation From the FDA for the Potential Treatment of ALS

Cytokinetics is posed to accererate clinical development of its troponin activator for the treatment of ALS after having been granted fast track status by the FDA. The expedited review process and more frequent interactions with the FDA are expected to facilitate evalution of the safety and efficacy of CK-2017357 and hopefully get it to ALS patients faster.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail